Published in Blood Weekly, September 28th, 2006
According to a recent report published in the journal Leukemia, researchers in People's Republic of China conducted a study "to assess the efficacy and toxicity of HAA regimen (homoharritonine 4mg/m2/day, days 1-3; cytarabine 150mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of AML, 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered into this clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.